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INTRODUCTION 
Hyperlipidemia is a major cause of atherosclerosis and 
atherosclerosis-associated conditions, such as coronary 
heart disease (CHD), ischemic cerebrovascular disease, 
and peripheral vascular disease.
1 
An overwhelming 
number of studies in the past decades have established 
dyslipidemia as the major risk factor for the development 
of atherosclerotic cardiovascular disease (CVD).
2
 The 
reported prevalence of CHD in India in adult surveys has 
risen 4-fold over the last 40 years (to a present level of 
around 10%) and even in rural areas the prevalence has 
doubled over the past 30 years (to a present level of 
around 4%).
3
 
The development of pharmacological interventions in 
particular, statins has been a major contributor to 
reduction of disease. Statins are now used by millions of 
people worldwide and their dramatic effect on 
cardiovascular disease has been shown in a large number 
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of trials and also in meta-analyses.
2
 Although statins are 
generally extremely well tolerated, statin intolerance does 
occur in some patients and requires careful consideration. 
In addition, patients are sometimes concerned about the 
potential risk of statins causing diabetes mellitus, cancer, 
and memory loss.
4
 Its safety has attached a great concern 
from scientists and researchers, such as transaminase and 
creatinine elevation, skeletal muscle pain and creatine 
kinase elevation. Therefore, developing novel classes of 
hypolipidemic agents which possess high efficiency and 
fewer adverse effects has still been a focus on the 
treatment of dyslipidemia.
5
 
Medicinal plants continue to play a central role in the 
healthcare system of large proportions of the world’s 
population. The advantages of herbal medicines reported 
are effectiveness, safety, affordability and acceptability.
6 
Tinospora Cordifolia (T.Cordifolia) is one such Indian 
medicinal plant which has been used in ayurvedic 
preparations through the centuries and is distributed 
throughout the tropical region of India. It has been shown 
to have hypolipidemic property in many experiments in 
diabetes-induced rats and rabbits. But very few reports 
are seen in non-diabetic rats. T. Cordifolia is already 
proven to be hepato-protective. Moreover this plant is 
cost-effective, easily available and less toxic.
7
 Therefore, 
this plant has been chosen to attempt to verify and 
evaluate the extent of its efficacy as a lipid lowering 
agent in cholesterol diet-induced hyperlipidemia in rats. 
METHODS 
The current study was conducted in the Central Animal 
House, department of pharmacology, A. J. Institute of 
Medical Sciences (AJIMS). The study was undertaken to 
evaluate hypolipidemic activity of aqueous root extract of 
T. cordifolia in cholesterol diet-induced hyperlipidemia 
in rats. 
Preparation of the extract 
The fresh roots of T.cordifolia were collected from 
Dakshina, Kannada district, Karnataka, India. 
Identification and extraction of the plant was done at the 
Srinivas College of Pharmacy, Mangalore, India. The 
roots of T. cordifolia were isolated, chopped into small 
pieces and dried under shade at room temperature for 
seven days. The dried roots were powdered and this 
powder was used for the preparation of aqueous extract 
by heat distillation process as detailed by Agarwal et al.
8 
The extract was assigned a code name TCrE. 
Animals 
Animals were procured from central animal house of 
department of pharmacology, AJ Institute of Medical 
Sciences, Mangalore, India. Healthy male albino rats of 
wistar strain (18-weeks-old), weighing 180-200 gm were 
used in the present study. They were inbred and grown 
under suitable laboratory conditions. They were housed 
two per cage in a room maintained at 12 h light-dark 
cycles and a constant temperature of 22±20 °C. The 
animals were provided with pellet chow and water ad 
libitum, except during experimentation. Animal 
experiments were conducted upon approval from the 
institutional animal ethics committee, AJIMS according 
to the CPCSEA guidelines of animal care. 
Grouping 
The method described by Ghule et al was employed in 
the study.
9
 Thirty healthy male Albino rats with similar 
body weight were selected. They were randomised into 
treatment and control groups. All rats were allowed a 
one-week acclimatization period to become accustomed 
to the laboratory conditions. Rats were randomly divided 
into five groups, each comprising six rats. 
Duration of the study 
The duration of the study was for 2 months which 
included 30 days of feeding period and next 30 days of 
treatment period with continued feeding.
9
 
Feeding period   
Group I served as normal control and was fed with 
standard rat chow throughout the study. Group II, III, IV 
and V were fed with high-fat diet for 30 days during the 
feeding period and then continued the same for the next 
30 days of treatment period. Rats were supplied food and 
water ad libitum.
9
 
Treatment period 
 Group I served as normal control (N) and received 
normal saline (5ml/kg, per oral) daily for 30 days. 
 Group II served as hyperlipidemic control (H) and 
received normal saline (5ml/kg, per oral) daily for 
30 days. 
 Group III served as standard drug control (R) and 
received Rosuvastatin (10 mg/kg, per oral) daily for 
30 days. 
 Group IV served as test group (TA) and received 
TCrE (2.5 g/kg, per oral) daily for 30 days. 
 Group V served as test group (TB) and received 
TCrE (5.0 g/kg, per oral) daily for 30 days. 
Induction of hyperlipidemia  
High cholesterol diet (HCD) comprised the following 
ingredients: cholesterol 5 g (Himedia Pvt Ltd, Mumbai), 
deoxycholic acid 5 g (Sigma-Aldrich Pvt Ltd, Mumbai), 
coconut oil 300 ml (300 g), and standard rat chow 700 g. 
Deoxycholic acid (5 g) was mixed thoroughly with 700 g 
of powdered rat chow diet. Simultaneously cholesterol 
(5g) was dissolved in 300 ml of warm coconut oil. This 
oil solution of cholesterol was added slowly into the 
powdered mixture and thoroughly mixed to obtain soft 
Sparshadeep EM et al. Int J Basic Clin Pharmacol. 2016 Aug;5(4):1286-1292 
                                              International Journal of Basic & Clinical Pharmacology | July-August 2016 | Vol 5 | Issue 4    Page 1288 
homogenous cakes. These cakes were daily supplied to 
rats in each cage in sufficient quantities.
10  
Body weight 
Body weights of all rats were checked on the day before 
the start of feeding period and on day 0, 15 and 30 of the 
treatment period.
9
 Total weight gain was calculated as: 
Total weight gain on day 30=Final body weight–Initial 
body weight  
Drug treatment 
Daily single dosage of TCrE (dissolved in normal saline, 
5 ml/kg) was given orally for 30 days in the treatment 
period to the test groups through oral gavage procedure. 
The control groups received normal saline alone. The 
standard group received rosuvastatin 10 mg/kg/day orally 
dissolved in 5 ml/kg normal saline. Doses of TCrE and 
rosuvastatin (Reddy labs Pvt Ltd, Hyderabad) were 
selected based on the reports in previous study which had 
hypolipidemic activity.
7,10,11
 All the doses were 
administered between 10-11 am. 
Blood sampling 
All blood samples were collected within a one-hour 
period between 8:00 am and 9:00 am. Twelve hours 
fasted blood samples were collected under light ether 
anaesthesia by retro orbital puncture. Blood samples were 
collected on the day before the start of feeding period and 
on day 0, 15 and 30 of the treatment period. These blood 
samples were used for serum lipid analysis.
9
 
Serum lipid analysis 
Serum lipid profile were analyzed for all rats on the day 
before the start of feeding period and on day 0, 15 and 30 
of the treatment period. Blood samples were allowed to 
clot for 30 minutes and serum was separated by 
centrifugation at 3,000 revolutions per minute (rpm) for 5 
minutes in Remi centrifuge (INCO, Chennai) and 
transferred to sterile 1.5mL centrifuge tubes.
9
 
Serum total cholesterol (TC), triglycerides (TG) and high 
density lipoprotein (HDL-C), low density lipoproteins 
(LDL-C), very low density lipoproteins (VLDL-C) were 
determined by endpoint colorimetric analysis using 
commercial kits and autoanalyser (Lablife Robochem, 
RFCL Ltd.) according to the manufacturer directions. 
Diagnostic reagent kit (RFCL Ltd, Dehradun) was used 
for estimation of triglycerides, total cholesterol and HDL-
C which used enzymatic glycerol-3-phosphate oxidase 
(GPO-ESPAS) and Cholesterol oxidase/peroxidase 
(CHOD-PAP) method.
12 
VLDL-C was calculated as one-
fifth the level of TG using empirical equation of 
Friedwald.
13
 The Friedewald method was used to 
calculate the LDL-C levels, which subtracts HDL-C and 
very low-density lipoprotein cholesterol (VLDL-C) from 
TC.
13
 
VLDL=TG/5 
LDL=TC−(HDL+VLDL) 
Percentage change from initial values (day 0 of treatment 
period) of serum lipid levels and body weights were 
calculated on day 15 and day 30 of treatment period using 
formula: Percentage change=[(difference in lipid 
levels/day0 lipid levels) X 100] 
Atherogenic index (AI) was calculated as AI=(total 
serum cholesterol/total serum HDL).
14 
Percentage protection from atherosclerosis was calculated 
as Protection (%)=[(difference in AI between control and 
treated group/AI of control) X 100] 
Statistical analysis 
Results were expressed as mean+standard deviation (SD) 
of six values (n=6) for each group. Statistical differences 
between the controls and the treatment groups were 
evaluated by using student’s unpaired and paired t-test 
wherever applicable using SPSS software package. 
Values were considered significant at p <0.05 and                   
p <0.01; highly significant at p <0.001. 
RESULTS 
Following were the effects seen in rats following 
administration of aqueous root extract of T.cordifolia 
(2.5/5 g/kg, p.o., once daily) and rosuvastatin (10 mg/kg, 
per oral, once daily).  
Effect on serum lipid levels 
Comparison with normal group  
On day 0 of treatment period the hyperlipidemic control 
group, rosuvastatin and test groups showed significant 
increase (p <0.001) in total cholesterol, triglyceride, LDL-
C, VLDL-C levels and significant decrease in HDL-C             
(p <0.05) levels (Table1, Figure1).  
Comparison with hyperlipidemic group 
On day 30 of treatment period Rosuvastatin group, Test 
group A and Test group B showed a significant decrease 
(p<0.001) in total cholesterol, triglyceride, LDL-C, 
VLDL-C levels and a significant increase (p<0.001) in 
HDL-C levels. (Table 1, Figure 2).  
Comparison with day 0 of treatment period (intragroup) 
A highly significant decrease in total cholesterol, 
triglyceride, LDL, VLDL levels and a significant increase 
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in HDL levels was observed in rosuvastatin group and 
both test groups on day15 (p<0.001) and day 30                      
(p <0.001) in the same group (Table 1, Figure 1,                 
Figure 2). 
Percentage change in lipid levels 
On day 30 when test groups were compared with 
rosuvastatin group they showed lesser percentage 
reduction in the serum total cholesterol, triglyceride, 
LDL-C and VLDL-C but test group B showed greater 
percentage elevation in the serum HDL-C than 
rosuvastatin group (Table 2). 
Effect on atherogenic index (AI) 
On day 30 the hyperlipidemic group showed a significant 
increase (p <0.001). The rosuvastatin and the test groups 
both reduced AI significantly (p <0.001). But the 
percentage protection against atherogenesis was greatest 
in the rosuvastatin group than in the test groups (Table 3). 
 
Table 1: Serum lipid levels and atherogenic index (AI) in various groups on Day 0, 15 and 30. 
Groups Day C (mg/dl) TG (mg/dl) HDL-C (mg/dl) VLDL-C (mg/dl) LDL-C (mg/dl) AI 
N 
0
 a1
 104.93+14.18 83.32+8.13 40.83+2.91 16.66+1.63 47.43+16.12 2.60+0.53 
15
 a2
 104.92+13.59 79.50+8.71 41.26+2.18 15.89+1.74 47.77+11.65 2.54+0.30 
30
 a3
 100.77+8.94 79.49+7.99 40.93+4.81 15.35+1.21 44.49+10.55 2.50+0.42 
H* 
0
 b1
 293.80+18.89 213.18+15.96 40.29+2.91 42.62+3.18 206.47+19.18 6.69+0.95 
15
 b2
 292.04+18.95 211.97+11.35 36.77+4.38 42.39+2.27 206.69+21.02 6.89+0.99 
30
 b3
 282.23+15.15 207.81+9.52 38.01+4.43 41.56+1.90 199.16+18.36 6.83+0.72 
R
#
 
0
 c1
 292.28+13.88 215.57+10.32 42.29+4.97 43.11+2.06 206.88+12.88 6.99+0.83 
15
c2
 196.53+15.67 158.27+16.02 50.78+2.33 31.65+3.20 99.62+15.00 3.03+0.39 
30
c3
 169.33+15.74 117.05+11.08 55.97+4.10 23.41+2.22 70.70+15.13 2.26+0.25 
TA
 #
 
0
 d1
 295.67+16.41 204.15+12.52 43.14+7.17 40.83+2.50 211.70+19.65 7.02+1.24 
15
d2
 272.29+13.28 186.82+13.87 48.49+4.82 37.36+2.77 186.44+14.66 5.65+0.53 
30
d3
 256.50+12.93 169.70+15.34 53.30+2.60 33.94+3.07 169.26+14.40 4.82+0.30 
TB
 #
 
0
 e1
 297.80+14.26 202.42+13.28 39.12+4.31 40.48+2.66 218.19+14.19 7.69+0.96 
15
 e2
 245.08+19.90 170.03+16.16 52.49+2.47 34.01+3.23 158.59+19.02 4.68+0.49 
30
 e3
 222.95+19.48 146.50+11.28 60.57+3.08 29.30+2.26 131.31+19.54 3.60+0.44 
Data expressed as Mean+SD of 6 observations. 
Student’s unpaired t-test: 
* Values are statistically highly significant at p<0.001when compared to normal control (N) 
# Satistically highly significant at p<0.001when compared to hyperlipidemic control (H) 
Student’s paired t-test: 
(a1 and a2), (a1 and a3): No significant difference, p>0.05; (b1 and b2), (b1 and b3):No significant difference, p >0.05; (c1 and c2), (c1 
and c3):Values are statistically significant at p<0.001; (d1 and d2), (d1 and d3):Values are statistically significant at p<0.001; (e1 and 
e2), (e1 and e3):Values are statistically significant at p<0.001 
 
 
Figure 1: Serum lipid levels on day 0. 
 
Figure 2: Serum lipid levels on day 30. 
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Table 2: Mean percentage change (%) from day 0 values of serum lipid levels in different groups on day 15 and 30. 
Groups Day 
Mean percentage change (%) 
C  TG  HDL-C  VLDL-C  LDL-C  
N 
15 0.21 4.54 1.45 4.60 4.64 
30 3.02 7.69 0.03 7.69 1.25 
H 
15 0.55 6.65 8.12 0.32 0.12 
30 3.83 2.29 5.35 2.26 3.49 
R 
15 32.80 26.66 21.59 26.66 51.96 
30 42.17 45.74 33.59 45.74 66.04 
TA 
15 7.84 8.49 13.56 8.49 11.74 
30 13.19 16.84 25.74 16.84 19.91 
TB 
15 17.78 16.05 35.21 16.05 27.39 
30 25.22 27.62 56.11 27.62 39.94 
Data expressed as mean of 6 observations. 
 
Effect on weight gain 
On day 30 the hyperlipidemic group showed a significant 
increase (p<0.01) while the rosuvastatin and the test 
group-B showed a significant decrease (p<0.001) in 
weight gain. But the test group-A showed no significant 
decrease (p >0.05) in weight gain (Table 4). 
Table 3: Atherogenic index (AI) in different groups on 
day 30. 
Groups Atherogenic index Protection (%) 
N 2.50 - 
H 7.5 - 
R 3.03 59.55 
TA 4.82 35.75 
TB 3.60 50.85 
Data expressed as mean of 6 observations. 
Table 4: Weight gain in different groups on day 30 as 
compared to day 0. 
Groups Weight gain (gm) 
N 6.66+2.58 
H 14.16+3.76 * 
R 7.5+2.73 
#
 
TA 10.0+4.47 
@
 
TB 9.16+3.76 
$
 
Data expressed as Mean+SD of 6 observations. Student’s 
unpaired t-test:* Highly significant difference when compared 
to normal control (N), p<0.01.#Highly significant difference 
when compared to Hyperlipidemic control, p<0.01.@ No 
significant difference when compared to Hyperlipidemic 
control, p>0.05.$ Significant difference when compared to 
Hyperlipidemic control, p<0.05. 
 
DISCUSSION 
It has been well established that nutrition plays an 
important role in the etiology of hyperlipidemias and 
atherosclerosis.
1
 This study has utilised deoxycholic acid, 
cholesterol, coconut oil and chow in the hyperlipidemic 
diet. A high-fat/high-cholesterol diet supplemented with 
cholic acid changes the lipoprotein profile to a more 
atherogenic one by increasing levels of LDL-C and 
lowering HDL-C.
15
 Many studies have shown that chow 
based diets supplemented with varying amounts of 
cholesterol and sodium cholate can induce 
hypercholesterolemia in mice and rats presumably by 
interfering with the hepatobiliary excretion of 
cholesterol.
16,17 
The mechanism of action of cholic acid is 
two-fold. It causes an increase in cholesterol absorption 
and a concomitant suppression of cholesterol 7α-
hydroxlyase activity that results in decreased cholesterol 
excretion. Cholic acid improves cholesterol absorption by 
its emulsifying property.
18
 
It is evident from the results that although both 
rosuvastatin and TCrE showed significant lipid lowering 
and HDL-C increasing activity, the percentage change in 
lipid parameter except for HDL-C was lesser with TCrE 
than with rosuvastatin. The explanation to this effect 
possibly lies in the difference in the mechanisms of 
hypolipidemic action of T. cordifolia and the rosuvastatin. 
Although multiple mechanisms have been suggested for 
T. cordifolia, none of those is suggested to affect the de 
novo synthesis of cholesterol like that by statins. Statins 
act by blocking the HMG-CoA reductase enzyme, which 
catalyzes the rate-limiting step in de novo cholesterol 
synthesis. Rosuvastatin is the most effective statin to 
lower LDL-C, with reductions of up to 63% reported with 
a daily dose of 40 miligram.
19
 
The exact mechanism by which TCrE reduced the serum 
cholesterol is not clear. But the observation of increased 
HDL-C levels could be one of the possible mechanisms 
for decrease in serum lipid levels by TCrE. The increased 
HDL-C facilitates the transport of TG or cholesterol by a 
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pathway termed ‘reverse cholesterol transport’ from 
serum to liver where it is catabolised and excreted out of 
the body. Increase of HDL-C is attributed to the 
mobilization of cholesterol from peripheral cells to the 
liver by the action of LCAT.
20
 
Studies have shown the presence of flavonoids, saponins, 
tannins, triterpenoids, steroids and polyphenolics in root 
extracts of T. cordifolia.
21
 Flavonoids are reported to 
enhance the activity of lecithin cholesterol acyl 
transferase (LCAT) which plays a key role in the 
incorporation of free cholesterol into HDL causing 
increase in HDL-C.
22
 Saponins are highly active plant 
compounds reported to increase faecal cholesterol 
excretion and also increase the lipoportein lipase activity 
(LPL)which helps in faster removal of free fatty acid from 
circulation consequently decreasing total cholesterol.
23,9
 
Tannins are reported to increase the activity of the 
endothelium bound lipoprotein lipase activity, which 
hydrolyzes triglycerides. Plant sterols are also reported to 
decrease cholesterol absorption and increase its 
excretion.
23
 
The TCrE also has anti-oxidant property.
24
 These phyto 
constituents would have contributed to the lipid lowering 
effect of TCrE in this study. But the presence of these 
phyto constituents in the TCrE needs to be investigated by 
further studies (such as phytochemical screening, fecal 
bile acid excretion). 
According to Kannel et al, an ideal drug is one which 
raises HDL-C along with the lowering of LDL-C.
25 
Biochemical estimations showed that both the TCrE as 
well as rosuvastatin increased the protective HDL-C level 
and decreased the atherogenic LDL-C and VLDL-C 
levels. Although TCrE has shown greater elevation of 
HDL-C when compared to rosuvastatin, the percentage 
protection from atherosclerosis remains the similar. This 
is an important advantage in treatment of 
hypercholesterolemia particularly among Indians where 
low HDL-C is the most prevalent lipoprotein 
abnormality.
26
  
High levels of total cholesterol and most importantly, 
LDL-C are the predictors of atherosclerosis.
27
 TCrE 
significantly reduced both the total cholesterol and LDL-
C. Recent studies show that triglycerides are directly or 
indirectly related to coronary heart diseases. In the present 
study, TCrE has markedly decreased the triglycerides 
level. These effects (although to a greater extent with 
rosuvastatin) along with significant decline in atherogenic 
index without causing mortality or adverse effects in rats, 
points towards the efficacious role of T.cordifolia as 
hypolipidemic agent.  
The pleotropic actions and the distinct mechanism of 
hypolipidemic action definitely assign the statins as the 
clinically most efficacious hypolipidemic agents. But the 
significant decrease in lipid profile, elevation in the HDL, 
good safety margin in experimental models combined 
with traditional application as cardioprotective agent 
definitely promote T.cordifolia as an agent to be clinically 
tested for the treatment of hyperlipidemia and its 
associated cardiovascular disorders. 
CONCLUSION 
The result shows that the T. cordifolia has a definite 
hypolipidemic and hence cardioprotective and 
antiatherosclerotic potential. There is also a valid 
scientific basis for consuming it for clinical benefits in the 
treatment of cardiovascular diseases in India. Hence, the 
present study helps to support the traditionally claimed 
cardioprotective activity of T. cordifolia. However, 
further studies are necessary to support these findings. 
Also an extensive case-control study is required to 
document its therapeutic application in human beings.   
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